Back to dashboard
CommercialCoverageMedium impact

08.02.30, Imetelstat (Rytelo™)

Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
May 19, 2025
We identified it
Jun 19, 2026
Days to comply
—

Summary

IBX has implemented a new commercial policy for Imetelstat (Rytelo™), a pharmacy benefit medication. This appears to establish coverage criteria and billing guidelines for this newly approved drug therapy.

Action Required

Action needed
Before May 19, 2025: Billing team should review the full policy details at the provided URL to understand coverage criteria, prior authorization requirements, and billing procedures for Imetelstat (Rytelo™). Update pharmacy benefit protocols and staff training materials accordingly.

Related policy hubs